Avadel Pharmaceuticals (AVDL) Beginning Cash Balance: 2009-2022
Historic Beginning Cash Balance for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Dec 2022 value amounting to -$13.3 million.
- Avadel Pharmaceuticals' Beginning Cash Balance fell 122.81% to -$13.3 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$23.3 million, marking a year-over-year decrease of 132.45%. This contributed to the annual value of -$20.2 million for FY2024, which is 147.19% down from last year.
- According to the latest figures from Q4 2022, Avadel Pharmaceuticals' Beginning Cash Balance is -$13.3 million, which was down 124.51% from $54.1 million recorded in Q3 2022.
- Over the past 5 years, Avadel Pharmaceuticals' Beginning Cash Balance peaked at $102.2 million during Q3 2020, and registered a low of -$13.3 million during Q4 2022.
- For the 3-year period, Avadel Pharmaceuticals' Beginning Cash Balance averaged around $56.4 million, with its median value being $60.0 million (2021).
- Per our database at Business Quant, Avadel Pharmaceuticals' Beginning Cash Balance skyrocketed by 663.30% in 2020 and then crashed by 122.81% in 2022.
- Avadel Pharmaceuticals' Beginning Cash Balance (MRQ) stood at $17.8 million in 2018, then dropped by 27.86% to $12.9 million in 2019, then soared by 545.91% to $83.1 million in 2020, then tumbled by 30.01% to $58.2 million in 2021, then crashed by 122.81% to -$13.3 million in 2022.
- Its last three reported values are -$13.3 million in Q4 2022, $54.1 million for Q3 2022, and $60.9 million during Q2 2022.